Key Events This Week
21 Sep: Surge in call and put option activity ahead of September expiry
24 Sep: Notable 11.6% increase in derivatives open interest amid mixed price action
25 Sep: Week closes at Rs.1,853.50 (+0.98%) outperforming Sensex
Monday, 21 September: Bullish and Bearish Option Activity Signals Mixed Sentiment
Sun Pharmaceutical began the week on a strong note, closing at Rs.1,868.00, up 1.77% on the day, outperforming the Sensex’s 0.46% gain. The stock saw a surge in call option volumes, particularly at the ₹1,880 and ₹1,900 strike prices, with over 28,500 contracts traded combined. This activity indicated bullish positioning by traders anticipating an upward move ahead of the 29 September expiry.
Simultaneously, heavy put option activity was observed at the ₹1,860 strike, with 6,089 contracts traded, signalling increased hedging or bearish bets. The proximity of the put strike to the spot price of Rs.1,885.30 suggested that investors were cautious about potential near-term corrections despite the positive price action. The stock’s technical setup showed strength above its 5-day, 100-day, and 200-day moving averages, though resistance remained near the 20-day and 50-day averages.
Investor participation was robust, with delivery volumes on 18 September rising by 111.83% to 21.06 lakh shares, underscoring genuine buying interest rather than speculative trading. The stock’s Mojo Score stood at 67.0 with a Hold rating, reflecting a tempered analyst outlook amid mixed signals.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Tuesday, 22 September: Price Correction Amid Broader Market Weakness
On 22 September, Sun Pharmaceutical’s share price corrected by 1.28% to close at Rs.1,844.00, underperforming the Sensex which declined 0.32%. The drop followed the previous day’s mixed derivatives activity and may reflect profit-taking or cautious repositioning ahead of expiry. Volume declined to 47,251 shares, indicating reduced trading interest compared to Monday.
The stock remained above key longer-term moving averages, maintaining technical support despite the pullback. The correction aligned with the broader sector’s modest weakness, suggesting a consolidation phase rather than a reversal of the recent uptrend.
Wednesday, 23 September: Recovery Supported by Positive Market Sentiment
Sun Pharmaceutical rebounded on 23 September, gaining 1.14% to close at Rs.1,865.00, outperforming the Sensex’s 0.56% rise. The recovery was supported by renewed call option interest and a narrowing of the price range, signalling stabilisation. However, delivery volumes dropped sharply by 48.54% compared to the five-day average, indicating a shift towards more speculative or short-term trading rather than long-term accumulation.
The stock’s technical indicators remained mixed, with price above the 200-day moving average but below shorter-term averages, reflecting a consolidation pattern. The Mojo Grade Hold rating continued to temper enthusiasm despite the positive price action.
Thursday, 24 September: Surge in Derivatives Open Interest Amid Price Underperformance
On 24 September, Sun Pharmaceutical experienced a notable 11.6% increase in derivatives open interest, rising from 85,520 to 95,442 contracts. Futures volume was robust at 70,342 contracts, with combined futures and options turnover exceeding ₹13,66,47 lakhs, highlighting strong market activity and liquidity.
Despite this surge, the stock closed down 0.64% at Rs.1,853.00, underperforming both its sector (-0.46%) and the Sensex (-1.62%). The narrow intraday range of ₹0.3 suggested limited price volatility amid active repositioning. Technical analysis showed the stock trading above its 200-day moving average but below the 5-day, 20-day, 50-day, and 100-day averages, indicating a mixed trend with longer-term support but subdued near-term momentum.
The decline in delivery volumes and the divergence between price action and derivatives activity pointed to a complex market outlook, with participants balancing hedging and speculative strategies.
Why settle for Sun Pharmaceutical Industries Ltd? SwitchER evaluates this large-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Friday, 25 September: Week Ends with Marginal Gain Amid Market Volatility
Sun Pharmaceutical closed the week at Rs.1,853.50, up a marginal 0.03% on the day, maintaining its weekly gain of 0.98%. The Sensex rose 0.18% on Friday but ended the week down 0.76%, underscoring Sun Pharma’s relative outperformance. Volume was subdued at 18,791 shares, reflecting cautious trading ahead of the weekend and expiry.
The stock’s ability to hold above Rs.1,850 despite broader market volatility and mixed technical signals suggests underlying resilience. The Mojo Score of 67.0 and Hold rating remain in place, indicating a balanced outlook with neither strong bullish nor bearish conviction.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-21 | Rs.1,868.00 | +1.77% | 35,787.64 | +0.46% |
| 2026-09-22 | Rs.1,844.00 | -1.28% | 35,672.04 | -0.32% |
| 2026-09-23 | Rs.1,865.00 | +1.14% | 35,870.78 | +0.56% |
| 2026-09-24 | Rs.1,853.00 | -0.64% | 35,291.38 | -1.62% |
| 2026-09-25 | Rs.1,853.50 | +0.03% | 35,353.29 | +0.18% |
Key Takeaways
1. Mixed Derivatives Activity Reflects Balanced Market Sentiment: The simultaneous surge in call and put option volumes ahead of the 29 September expiry indicates that investors are both positioning for upside potential and hedging against downside risks. This duality suggests a cautious but opportunistic stance.
2. Relative Outperformance Despite Sector and Market Volatility: Sun Pharmaceutical’s 0.98% weekly gain contrasts with the Sensex’s 0.76% decline, highlighting the stock’s defensive qualities and sectoral resilience amid broader market uncertainty.
3. Technical Indicators Signal Consolidation: The stock’s position above the 200-day moving average but below shorter-term averages points to a consolidation phase. Investors should watch for a breakout or breakdown from this range to gauge the next directional move.
4. Mojo Grade Downgrade to Hold Tempered Optimism: The downgrade from Buy to Hold on 3 September 2026 reflects analyst caution, likely due to valuation concerns and mixed technical signals. This rating aligns with the observed market behaviour of balanced bullish and bearish positioning.
Conclusion
Sun Pharmaceutical Industries Ltd’s performance during the week ending 25 September 2026 was characterised by a delicate balance between optimism and caution. The stock’s modest 0.98% gain and outperformance relative to the Sensex underscore its resilience within a volatile market environment. However, the mixed derivatives activity, declining delivery volumes, and technical consolidation suggest that investors remain watchful ahead of the September expiry.
The notable surge in open interest and active options trading highlight the stock’s liquidity and importance as a sector bellwether, but also signal that market participants are hedging their bets amid uncertain near-term catalysts. The Hold rating and Mojo Score of 67.0 further reinforce a prudent approach, favouring observation over aggressive positioning.
Going forward, price action around key moving averages and expiry outcomes will be critical in determining whether Sun Pharmaceutical can sustain its gains or faces a corrective phase. For now, the stock remains a focal point for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a balanced risk-reward profile.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
